Ms. Morton, R.Ph., M.B.A., is Vice President of Cardiovascular Marketing at Boehringer-Ingelheim. She has 25 years of experience in the pharmaceutical industry in marketing, sales, managed care, and customer relations. Prior to joining B-I, she was vice president of the Transplant Business Franchise for Novartis, worked in the Worldwide Medicines Group for Bristol-Myers Squibb, and was a Drug Information Specialist at the University of Rochester.
Mr. Bette is Principal and co-founder of Bette and Cring, a diversified construction management, design-build, and general contracting firm. He has more than 30 years of experience in the construction industry and has been responsible for the successful delivery of over one billion dollars of construction projects. Along with his brother Peter, he helps lead the overall operations of the company.
Mr. Mitiguy retired from family-owned Burlington Drug Company (BDC) in 2013 and now works as a pharmaceuticals consultant. BDC is the largest independent drug wholesaler in New England. He served as Vice President of both BDC and its parent company, Cobble Hill Holdings. Mr. Mitiguy, who has more than 30 years experience in the industry, is also past chair of Healthcare Distribution Management Association.
Mrs. Daley, R.Ph., M.B.A., is a pharmacist with Kinney Drugs in the Health Direct Division. Prior to her current position, she was Pharmacy Services Manager for the New York Group of Eckerd Corporation where she was responsible for the pharmacy operations of 449 stores in New York State, northern New Jersey, and Connecticut. She served as Chair of the ACPHS Board of Trustees from 2003 to 2009.
Stephen Ainlay, Ph.D. became the 18th president of Union College on July 1, 2006. He also serves as the chancellor of Union University, whose member institutions include Albany College of Pharmacy and Health Sciences, Albany Law School, Albany Medical College, Union Graduate College, and the Dudley Observatory. Before joining Union, President Ainlay spent 23 years at the College of the Holy Cross in Worcester, MA.
Mr. Bleser is Owner and President of Northeastern Fine Jewelry, formally founded in 1986 and now with three locations. It is the largest independently-owned jeweler in the Capital Region of New York State and is a member of The Leading Jewelers in the World group. Ray also serves as secretary of the Board of Directors of Proctor's Theatre in Schenectady, NY, and is a past member of the St. Claire's Hospital Board of Directors.
Mr. Borisenok co-founded Fortitech, Inc., in 1986 and served as its President until the sale of the company in November 2012. Fortitech's custom additives blend vitamins, minerals, and other nutrients to help boost the energy and nutritional content of a wide range of food and beverage products. At the time of its sale, Fortitech had 500 employees and operations in nine countries.
Ms. Briscoe-Dwyer, R.Ph., Pharm.D., BCPS, is Chief Pharmacy and Medication Safety Officer at North Shore LIJ Health System. Previously, she was Director of Pharmaceutical Care Services for Bassett Healthcare in Cooperstown, NY, and served as a Clinical Education Consultant for Pfizer. She is a Past President of the New York State Council of Health-system Pharmacists and a member of the New York State Board of Pharmacy.
Mr. Chorbajian was the Chief Executive Officer of Albank (formerly Albany Savings Bank) from 1990-1998. From 1984-1990, he served as Albank's President and COO. Following Albank's merger with Charter One Financial Corporation, he continued in the role of Vice Chair until Charter One was acquired by Citizens Financial Group in 2004. Prior to joining Albank, he served as CFO for Norstar Bancorp.
Thomas D’Ambra, Ph.D., co-founded Albany Molecular Research, Inc., (AMRI) in 1991 and served as President and Chief Executive Officer until his retirement in 2013. He is currently Chairman of the Board at the publicly-held company. AMRI developed the active ingredient in the allergy medication Allegra. The global contract research and manufacturing organization has locations in North America, Europe, and Asia.
Paul DerOhannesian II, J.D., is a civil and criminal litigation attorney at the firm DerOhannesian and DerOhannesian in Albany, NY. Prior to joining the firm, Mr. DerOhannesian was an assistant district attorney with the Albany County District Attorney's Office and for 22 years headed the D.A.'s Special Assault Unit. He is the author of a definitive two-volume text, Sexual Assault Trials, Fourth Edition.
James E. Dering, J.D., is a partner at Garfunkel Wild, P.C., a law firm specializing in the business and legal needs of clients in the health care industry. He previously served as General Counsel of the New York State Department of Health for nearly five years, where he was the chief legal advisor to the Commissioner of Health and oversaw approximately 125 attorneys and staff.
Chris Di Lascia, Pharm.D., is the President, CEO, and co-founder of Transition Patient Services (TPS). He was previously employed with Aventis Pharmaceuticals where he held the position of Global Marketing Director for Lovenox. He began his pharmaceutical industry career in 1988 as a Hospital Sales Representative with Eli Lilly and Company before leaving to join Schering-Plough as a Managed Care and Government Affairs Manager in 1990.
Mr. Duteau, R.Ph., is Vice President of Business Development and Strategic Relations at Kinney Drugs. Prior to joining Kinney in 2006, he was District Pharmacy Supervisor for Eckerd Corporation where he managed 80 pharmacies in Central and Eastern New York State. He is the current president of the New York State Chain Pharmacy Association and a past Chairman (2012-13) of the New York State Board of Pharmacy.
Mr. Germano is the Group President of Pfizer’s Global Innovative Pharma Business – one of the company’s three global operating units. He leads the clinical development, registration, and commercialization of the company’s assets in this unit. He also serves on the Advisory Board of the Healthcare Businesswomen’s Association and is a member of the Board of the Biotechnology Industry Organization.
Mr. Giruzzi, R.Ph., is retired owner of two independent pharmacies - Fort Schuyler Pharmacy (1962-78) and South Utica Pharmacy (1976 to 1990). He is Past President and Chair of the Pharmacists Society of the State of New York (PSSNY) and a board member of the New York State Board of Pharmacy. Mr. Giruzzi is serving his fourth three-year term as a trustee of the College.
Susan Learned, Pharm.D., M.D., Ph.D., is the Senior Vice President of Global Clinical Development at Indivior, Inc. Dr. Learned joined Indivior in 2015, after serving as the Vice President, Medicines Development Leader and Head of the Psoriasis and Atopic Dermatitis Care Areas at Stiefel, a GlaxoSmithKline (GSK) company. She spent nearly 20 years at GSK leading various global neurosciences clinical divisions.
James Notaro, R.Ph., Ph.D., is the Founder and President of Clinical Support Services (CSS), Inc., a Buffalo-based provider of medication management solutions. Prior to founding CSS in 1999, he held executive positions with Univera Health Care and was Director of Managed Care Programs/Research & Development with Centrus, an Albany-based prescription benefit management company.
David Stack is Chairman and CEO of Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company focused on non-opioid medication products for pain management. Mr. Stack has shepherded several therapeutics through clinical development and FDA approval, including the successful commercial launch of the pain control product EXPAREL. In addition to his role with Pacira, Mr. Stack is also a Managing Director at MPM Capital, a venture capital firm focused on life sciences companies.
Mr. Terrillion, J.D., is Vice President, Associate General Counsel, and Head of Compliance at Mesoblast Ltd., a regenerative medicine company headquartered in Australia. He began his career as Director of Pharmacy at Preferred Care (now MVP Health Care) before joining Boehringer-Ingelheim in 1998. He spent 17 years at B-I where he rose to the position of Vice President and Group General Counsel.
As the Principal and Founder of Williamson BioPharma Consulting, Pamela Williamson, RAC, FRAPS, MBA, is an independent consultant for the bio-pharmaceutical industry with more than 30 years of global leadership experience. Ms. Williamson has a strong track record in the successful development and registration of products to treat patients with serious and life-threatening rare diseases. She most recently served as SVP of Global Regulatory Affairs & Patient Safety at Alexion Pharmaceuticals.